Back to funds
View filing
JOHNSON & JOHNSON
institutionalUpdated 35 days agoManaged by Johnson & Johnson • Latest filing Q2 2026
Portfolio value
$798.7M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
34.1%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $307.4M |
| Q2 2023 | $322.1M |
| Q3 2023 | $271.5M |
| Q4 2023 | $4.4B |
| Q1 2024 | $4.4B |
| Q2 2024 | $400.7M |
| Q3 2024 | $427.3M |
| Q4 2024 | $386.1M |
| Q1 2025 | $341.9M |
| Q2 2025 | $334.1M |
| Q3 2025 | $503.7M |
| Q4 2025 | $554.6M |
| Q1 2026 | $652.4M |
| Q2 2026 | $798.7M |
Top holdings
15 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | P PB PROTAGONIST THERAPEUTICS INC | $300.2M | 2.45M | 37.59% | Unchanged |
| 2 | N NNBXF NANOBIOTIX | $212M | 5.62M | 26.55% | Unchanged |
| 3 | M MGTX MEIRAGTX HLDGS PLC | $89.7M | 6.64M | 11.23% | Unchanged |
| 4 | R RAPP RAPPORT THERAPEUTICS INC | $74.4M | 1.78M | 9.31% | Unchanged |
| 5 | C CTNM CONTINEUM THERAPEUTICS INC | $32.4M | 1.98M | 4.06% | Unchanged |
| 6 | L LEGN LEGEND BIOTECH CORP | $23.5M | 814.6K | 2.95% | Unchanged |
| 7 | C CVRX CVRX INC | $20.7M | 4.02M | 2.59% | Unchanged |
| 8 | X XNCR XENCOR INC | $12M | 748.1K | 1.51% | Unchanged |
| 9 | C CBRS CEREBRAS SYSTEMS INC | $11.8M | 53.6K | 1.48% | — |
| 10 | F FATE FATE THERAPEUTICS INC | $9.1M | 3.38M | 1.14% | Unchanged |
| 11 | P PRCT PROCEPT BIOROBOTICS CORP | $8.1M | 357.9K | 1.01% | Unchanged |
| 12 | N NMRA NEUMORA THERAPEUTICS INC. | $3.1M | 1.85M | 0.39% | Unchanged |
| 13 | V VOR VOR BIOPHARMA INC | $989K | 53.7K | 0.12% | Unchanged |
| 14 | L LAB STANDARD BIOTOOLS INC | $257K | 312.0K | 0.03% | Unchanged |
| 15 | A ACET ADICET BIO INC | $197K | 22.8K | 0.02% | Unchanged |